FAC Explorer

Audit 403172

FY End
2025-12-31
Total Expended
$56.07M
Findings
0
Programs
67
Organization: La Jolla Institute for Immunology (CA)
Year: 2025 Accepted: 2026-06-05
Auditor: 301413443

Organization Exclusion Status:

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.855 Allergy and Infectious Diseases Research $21.58M Yes 0
93.384 Advanced Research Projects Agency for Health (ARPA-H) $9.02M Yes 0
93.855 Consortium for HIV/AIDS Vaccine Development $3.24M Yes 0
93.RD 75N93019C00001 IEDB-07 $3.24M Yes 0
93.396 Cancer Biology Research $1.80M Yes 0
93.855 Discovering Durable Pan-Coronavirus Immunity $1.31M Yes 0
93.393 Cancer Cause and Prevention Research $1.20M Yes 0
93.RD 75N93024C00057- Pneumonia $1.11M Yes 0
93.RD 75N93024C00056- PP $1.10M Yes 0
93.855 Flavivirus and Alphavirus ReVAMPP (FLARE) $963,664 Yes 0
93.859 Biomedical Research and Research Training $843,299 Yes 0
93.395 Cancer Treatment Research $794,079 Yes 0
93.855 Airway Inflammation and Airway Remodeling in Severe Asthma $755,200 Yes 0
93.351 Research Infrastructure Programs $687,033 Yes 0
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $489,056 Yes 0
93.855 The Development and Evaluation of Pan-Coronavirus Vaccines $454,526 Yes 0
93.855 Transcription factor regulation of CD4 and CD8 T cell effector and memory differentiation and function $438,409 Yes 0
93.353 Personalized neuroblastoma vaccines $433,449 Yes 0
93.RD Collaborative Influenza Vaccine Innovation Centers (CIVICs) Component A: Vaccine Center $424,546 Yes 0
93.847 TWEAK/TNFSF12 and LIGHT/TNFSF14 interactions in allergic esophagitis remodeling $392,472 Yes 0
93.RD 75N93019C00001- CD3 $389,000 Yes 0
93.RD Development of an Ebolavirus Sudan Vaccine Utilizing a Live Vesicular Stomatitis Virus Chimera Platform Contract A10322 - 324,941 $324,941 Yes 0
93.394 Cancer Detection and Diagnosis Research $318,870 Yes 0
93.RD The breadth of cross-reactivity of T cell responses elicited by different vaccination regimensmeasured against different Sarbeco and Merbeco viral sequences $314,076 Yes 0
93.384 Protect against Emergent Alphaviruses through Computation $305,205 Yes 0
93.855 B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection $299,219 Yes 0
93.839 Neutrophil lineage in inflammation $297,439 Yes 0
93.350 National Center for Advancing Translational Sciences $290,488 Yes 0
93.855 Immune engineering of optimized sequential immunization strategies for HIV vaccines $290,295 Yes 0
93.855 Evolution and Durability of Human T and B cell Responses $236,768 Yes 0
93.855 i-AKC: Integrated AIRR Knowledge Commons $233,221 Yes 0
93.855 Thermostable measles fusion glycoprotein as a new vaccine strategy $230,619 Yes 0
93.847 Eicosanoids, Chronic Kidney Disease Progression, and Associated Cardiovascular Risk $202,794 Yes 0
93.RD Cryoelectron Microscopy Support $178,980 Yes 0
93.866 Inflammatory Mediators of Sex Differences in Alzheimer's Disease, A Humans to Mouse Approach $152,730 Yes 0
93.855 Protective immunity following dengue virus natural infections and vaccination $139,144 Yes 0
93.395 Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer $138,497 Yes 0
93.394 SARS-CoV-2 correlates of protection in a Latin-orgin population $135,047 Yes 0
93.855 The function of atypical B cells in the immune response against malaria $116,359 Yes 0
93.RD 75N93019C0001- Bridge Funding $112,087 Yes 0
93.855 Childhood Asthma in Urban Settings Clinical Research Network (CAUSE) – Leadership Center $100,301 Yes 0
93.242 Dysregulation of TRIO GEF1 activity in nuerodevelopmental disorders. $91,654 Yes 0
93.837 Vaccine Induced Immune-Inflammatory Response and Cardiovascular Risk $88,605 Yes 0
93.395 Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer $83,265 Yes 0
93.RD Spheromer-Tetramer Comparison Study (STCS) $75,612 Yes 0
93.839 Ikaros regulation: study on hemo-lymphopoiesis $71,192 Yes 0
93.397 Specialized Cancer Center Core support gran $59,035 Yes 0
47.074 Mechanisms of a natural bacterial biosensor using RT-DNA $57,478 Yes 0
93.847 San Diego Digestive Diseases Research Center $54,189 Yes 0
93.855 Genetics Linkage in Lupus $43,468 Yes 0
93.395 Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy $42,354 Yes 0
93.855 Targeting of somatic hypermutation in the genome $40,173 Yes 0
93.855 Fusion peptide directed immunogens that elicit neutralizing and protective antibodies in non-human primates $38,848 Yes 0
93.395 Harnessing CMV-specific T cells for tumor immunotherapy $37,214 Yes 0
93.855 Emerging infections: surveillance, epidemiology and pathogenesis $32,802 Yes 0
93.310 Epigenetic regulation of epidermal proinflammatory responses $30,120 Yes 0
93.855 Semantic integration of protein epitopes and functional features for infectious and autoimmune disease knowledge discovery $27,659 Yes 0
93.855 IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alphagal) in murine and human atherosclerosis $25,893 Yes 0
93.RD 75N93019C00001 IEDB-06 $24,211 Yes 0
93.855 Development of Neutralizing Antibodies to Machupo Virus $22,091 Yes 0
93.310 Spatial mapping senescent cells across the mouse lifespan by multiplex transcriptions and epignenomics $18,735 Yes 0
93.395 Optimizing immunoradiotherapy for HNSCC $10,915 Yes 0
93.350 Direct Human Upper Airway Swab Sampling to Understand Mucosal Health and Disease $5,031 Yes 0
93.855 Immune Tolerance Network $3,819 Yes 0
93.855 Mechanism and Regulation of V(D)J Recombination $1,404 Yes 0
93.855 Identification and characterization of the class I and class II MHC molecules of the Syrian hamster to enable advanced studies of T cell immunity $1,391 Yes 0
93.RD 75N93019C00001 IEDB -05 $-187 Yes 0

Contacts

Name Title Type
ZPAUY3FQMM26 Victoria Kern Auditee
8587526557 Scott Simpson Auditor
No contacts on file

Notes to SEFA

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of La Jolla Institute for Immunology (the Institute) under programs of the federal government for the year ended December 31, 2025. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because it presents only a selected portion of the operations of the Institute, it is not intended to, and does not, present the financial position, changes in net assets, or cash flows of the Institute.